Salud

Bristol-Myers Squibb to buy Amylin for about $5.3 billion

(Reuters) - Bristol-Myers Squibb Co agreed to buy Amylin Pharmaceuticals Inc for about $5.3 billion, or for $31 per share in cash.

Bristol-Myers Squibb said it will finance the acquisition from its existing cash resources and credit facilities.

Transactions are expected to be dilutive to adjusted earnings in 2012 and 2013 by about 3 cents, the company said in a statement.

(Reporting by Chandni Doulatramani in Bangalore; editing by Carol Bishopric)

WhatsAppWhatsApp
FacebookFacebook
TwitterTwitter
Google+Google plus
Linkedinlinkedin
emailemail
imprimirprint
Publicidad
Otras noticias
Contenido patrocinado